Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026

Key Takeaways

• cema-cel Phase 2 ALPHA3 trial enrolling >60 sites worldwide
• Interim futility analysis scheduled April 2026 compares MRD clearance
• ALLO-329 targets CD19/CD70, aims to avoid lymphodepletion
• First dosing cohort data for ALLO-329 expected June 2026
• Allogene remains clinical‑stage biotech focusing on off‑the‑shelf CAR‑T

Summary

Allogene Therapeutics announced that its lead CAR‑T candidate cema‑cel remains on schedule in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation of large B‑cell lymphoma, now enrolling at more than 60 sites worldwide. An interim futility analysis is set for April 2026, focusing on measurable residual disease clearance and early safety versus observation. The company also highlighted progress on ALLO‑329, a dual CD19/CD70 AlloCAR‑T designed to eliminate conventional lymphodepletion, with Phase 1 dose‑escalation data expected in June 2026. These updates keep Allogene on track to advance both oncology and autoimmune pipelines.

Pulse Analysis

Allogene Therapeutics’ cema‑cel program targets measurable residual disease (MRD) as a biomarker for early consolidation in large B‑cell lymphoma, a strategy that could dramatically reduce relapse rates. By leveraging an allogeneic, off‑the‑shelf CAR‑T construct, the company sidesteps the lengthy manufacturing timelines that have hampered autologous therapies, positioning itself to capture a share of the projected $8 billion LBCL market. The upcoming interim futility analysis in April will be a critical data point for investors, as it benchmarks MRD clearance against standard observation and informs the design of later‑stage trials.

Beyond oncology, Allogene’s ALLO‑329 candidate showcases the versatility of its Dagger platform, which integrates CD19 and CD70 targeting while aiming to eliminate the need for pre‑infusion lymphodepletion. This could lower treatment toxicity and broaden applicability across autoimmune conditions such as systemic lupus erythematosus and scleroderma. Early Phase 1 enrollment across multiple indications signals confidence in the technology’s safety profile, and data expected in June 2026 may set a new precedent for CAR‑T use in non‑cancer diseases.

From an investment perspective, Allogene’s dual‑track approach mitigates risk by diversifying revenue potential across oncology and autoimmune markets. Regulatory pathways for allogeneic CAR‑T products are still evolving, but successful interim results could accelerate FDA discussions and attract partnership interest. As competitors like Legend and Autolus push autologous solutions, Allogene’s off‑the‑shelf model offers a compelling cost‑and‑time advantage, potentially translating into faster market entry and stronger valuation upside.